CRP and chronic kidney disease: For example, Domanski et al. [12] noted a 62% reduction in all-cause mortality (HR 0.38, 95% CI 0.18-0.82, p = 0.0134) among patients with non-ischemic dilated cardiomyopathy, while Ridker et al. [15] found that rosuvastatin led to a 45% reduction in major CV events (HR 0.55, 95% CI 0.38-0.82, p = 0.002) in patients with CKD and elevated C-reactive protein (CRP).